-
Part 3 | Session 10 Lifetime Benefit by Control of Modifiable Risk Factors
-
Part 3 | Session 11 CardiAMP-HF: Autologous Cell Therapy in Patients With HFrEF
-
Part 4 | Session 1 4 Trials That Will Change My Practice with Dr Ambarish Pandey
-
Part 4 | Session 2 4 Trials That Will Change My Practice with Dr Dipti Itchhaporia
-
Part 1 | Session 1 View from the Thoraxcenter: What's Hot at ACC.25?
-
Part 1 | Session 2 View from the Thoraxcenter: ACC 25 Wrap-Up
-
Part 2 | Session 1 ADVANCE-HTN: Lorundrostat in Patients with Uncontrolled Hypertension
-
Part 2 | Session 2 STRIDE: Semaglutide for Functional Capacity in Patients with T2D and PAD
-
Part 2 | Session 3 API-CAT: Reduced Vs Full Dose Apixaban for Cancer-Associated Thrombosis
-
Part 2 | Session 4 FRESH-UP: Liberal Intake Vs Fluid Restriction in Chronic Heart Failure
-
Part 2 | Session 5 SOUL: Semaglutide in Patients with T2D
-
Part 2 | Session 6 BHF PROTECT-TAVI: Cerebral Embolic Protection in TAVI
-
Part 3 | Session 1 The Phase 3 REVERSE-IT Trial
-
Part 3 | Session 2 EVOLUT Low Risk: 5Y Outcomes After TAVR or SAVR in Low-Risk Patients with AS
-
Part 3 | Session 3 SMART-CHOICE 3: Clopidogrel vs Aspirin Monotherapy in High-Risk PCI Patients
ACC 25 - Findings of the MIGHTy-Heart study shows no difference between mobile integrated healthcare and a traditional transitions of care coordinator approach in 30-day all-cause readmissions or health status.
Dr Ruth Masterson Creber (Columbia University, New York, US) joins us onsite at ACC to discuss the findings from MIGHTy-Heart, a comparative effectiveness study that evaluated two different post-discharge care approaches for patients hospitalized with heart failure. (NCT04662541) The trial compared a traditional Transitions of Care Coordinator approach to a Mobile Integrated Health model to determine which was more effective at reducing 30-day hospital readmissions and improving patient-reported health-related quality of life.
Findings showed no difference between the two study arms in 30-day all-cause readmissions or health status, however there were significant interaction effects that suggest women and younger patients could benefit from MIH intervention over the TOCC intervention.
Interview Questions:
1. What is the importance of this study?
2. Could you tell us about the study design and patient population?
3. What training was required for the community paramedics to effectively manage heart failure patients in the home setting?
4. What are the key outcomes?
5. What implications do these findings have for heart failure care models, particularly in rural or underserved areas?
6. What are your key take-home messages?
Recorded onsite at the ACC Conference 2025, in Chicago.
Editors: Jordan Rance, Yazmin Sadik
Video Specialists: Dan Brent, David Ben-Harosh
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the most influential trials.
Comments